公开(公告)号：AU2003236346A1

公开(公告)日：2003-10-20

申请号：AU2003236346

申请日：2003-04-08

Applicant: KUROKAWA KIYOSHI ,  MIYATA TOSHIO ,  FUSO PHARMACEUTICAL IND

Inventor： MIYATA TOSHIO ,  CHISAKA TAKESHI ,  KUNITOU KAZUYA ,  ASAKURA MASAHIRO ,  HIROOKA YUMI ,  KUROKAWA KIYOSHI

IPC: C07K16/18 ,  C12N5/20 ,  C12P21/08 ,  A61K39/00

公开(公告)号：JP2000002703A

公开(公告)日：2000-01-07

申请号：JP16828598

申请日：1998-06-16

Applicant: FUSO PHARMACEUTICAL IND

Inventor： UEMURA HIDETOSHI ,  KISHI YUICHIRO ,  KUNITO KAZUYA ,  HIROOKA YUMI

IPC: G01N33/50 ,  A61K9/16 ,  A61K39/395 ,  C07K16/18 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543

Abstract: PROBLEM TO BE SOLVED: To judge the diagnosis and critical degree of renal disease by bringing a second antibody having a labeled molecule connected thereto into contact with a biological sample and a subject having a first antibody brought into contact with the surface of a solid granule, and detecting the labeled molecule connected to a complement control factor. SOLUTION: With respect to urine and serum of a normal person and a renal disease patient, MCP quantity (membrane cofactor protein) is measured. A magnetic bead having a monoclonal antibody 177, a subject and a POD labeled monoclonal antibody M160 are reacted to focus and fix the bead by the magnet, and the supernatant is disposed. After washing, a substrate solution is added to further react them, and the bead is focused and fixed by the magnet, and the supernatant is collected to measure the absorbance. The serum MCP value is measured by use of the monoclonal antibody M160 and also by use of the POD labeled monoclonal antibody M160 as the detecting antibody. As a result of the measurement, the MCP values in urine and serum are distributed in high level in the renal disease patient, compared with the normal person, and also high in a more critical patient.